Overview

Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as irofulven, use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well irofulven works in treating patients with recurrent or metastatic gastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Therapeutics Research Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
Irofulven